Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04333927 | Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer(ACCORD) | unknown | Phase 2 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT04386772 | Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma | unknown | N/A | 56 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 |
| Jun 17, 2020 |
| clinicaltrials |
| NCT04434989 | SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma(SAIL) | unknown | N/A | 170 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04435977 | Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma(Immunocabo) | unknown | Phase 2 | 46 | Istituto Clinico HumanitasOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT02971345 | Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus | unknown | Phase 3 | 253 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT02599662 | Intraoperative Radiation Therapy for Resectable Pancreas Cancer(IORT) | unknown | Phase 1 | 12 | Loyola UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04414956 | Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma | unknown | N/A | 1,418 | Korea UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04415190 | the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients | unknown | — | 150 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT03588442 | Prospective Surveillance for Very Early Hepatocellular Carcinoma(PRECAR) | unknown | — | 10,000 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT03780049 | HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B | unknown | Phase 3 | 304 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT04392700 | A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection | unknown | Phase 3 | 706 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT04380506 | Validations of New cut-of for the Stratification of Postoperative Complications,Drains Management(DALCUT) | unknown | N/A | 165 | Campus Bio-Medico UniversityOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT04368182 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 3 | Zhejiang UniversityOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT03592706 | Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | unknown | Phase 2 / Phase 3 | 60 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT03116984 | A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC(TACE-EBRT) | unknown | Phase 3 | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03971747 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 9 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Apr 7, 2020 | clinicaltrials |
| NCT04080154 | Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma(ALTER-H-002) | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT04143191 | Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC(SOURCE) | unknown | Phase 3 | 158 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04237740 | Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation(RRHCCLT) | unknown | Phase 3 | 40 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT04319484 | Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(LLTHVV) | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT04163627 | Changing Trends in HCC Procedures | unknown | — | 1,000 | University Hospital, MontpellierOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04189809 | Discrepancies in Management of Hepatocellualr Carcinoma Between Practice and Recommendations | unknown | — | 1,000 | University Hospital, MontpellierOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04299919 | The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment | unknown | — | 1,200 | The First Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT02635971 | Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 168 | Fudan UniversityOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT03840460 | A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers(PaC-MAn) | unknown | — | 200 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT04273100 | PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC(PLTHCC) | unknown | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04269369 | Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients | unknown | Phase 4 | 250 | Jessa HospitalOTHER | 0 | Feb 13, 2020 | clinicaltrials |
| NCT02504983 | Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma | unknown | Phase 4 | 200 | Chang Gung Memorial HospitalOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03969576 | Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC) | unknown | N/A | 344 | Air Force Military Medical University, ChinaOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04239781 | A Survey for Factors That Influence Postoperative Treatment Decision-making for Hepatocellular Carcinoma | unknown | — | 2,500 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04241523 | Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04243057 | Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study | unknown | — | 5,000 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03211598 | Surefire Institutional DEB-TACE | unknown | N/A | 15 | Alexander KimOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04220151 | Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C | unknown | — | 100 | Assiut UniversityOTHER | 0 | Jan 14, 2020 | clinicaltrials |
| NCT04227808 | Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04221347 | Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC | unknown | — | 250 | Military University Hospital, PragueOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02436902 | Adjuvant Therapies for Patients With HCC and MVI(A-TACE/S-HCC) | unknown | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04193696 | RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC) | unknown | Phase 2 | 39 | Guangxi Medical UniversityOTHER | 0 | Jan 9, 2020 | clinicaltrials |
| NCT04209491 | Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway(INFIC) | unknown | — | 1,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT03544255 | Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues | unknown | — | 50 | Ying LvOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04204577 | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT04202523 | Combined Radiotherapy and Radiofrequency Ablation for Hepatocellular Carcinoma | unknown | Phase 3 | 50 | Guangxi Medical UniversityOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04189393 | Microbiome Analysis in esoPhageal, PancreatIc and Colorectal CaNcer Patients Undergoing Gastrointestinal Surgery(MA-PPING) | unknown | — | 60 | Radboud University Medical CenterOTHER | 0 | Dec 6, 2019 | clinicaltrials |
| NCT03771846 | HAIC Versus Systemic Chemotherapy for Unresectable ICC | unknown | Phase 3 | 188 | Shi MingOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT04157140 | Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | unknown | Phase 2 | 48 | Jinglong ChenOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT03851913 | The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy | unknown | Phase 3 | 344 | Sun Yat-sen UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jun 23, 2020source: clinicaltrials